Pifeltro is owned by Msd Merck Co.

Pifeltro contains Doravirine.

Pifeltro has a total of 1 drug patent out of which 0 drug patents have expired.

Pifeltro was authorised for market use on 30 August, 2018.

Pifeltro is available in tablet;oral dosage forms.

Pifeltro can be used as for use in combination with other antiretroviral agents for the treatment of hiv-1 as a replacement therapy in virologically suppressed adults with no history of treatment failure and no known substitutions associated with resistance to doravirine; for use in combination with other antiretroviral agents for the treatment of hiv-1 infection in adult patients with no prior antiretroviral treatment history; for use in combination with other antiretroviral agents to treat hiv-1 infection in pediatric patients weighing at least 35kg with no prior antiretroviral treatment history or to replace the current antiretroviral regimen if virologically suppressed.

Drug patent challenges can be filed against Pifeltro from 2022-08-30.

The generics of Pifeltro are possible to be released after 07 October, 2031.